The Rapid Response: Canada program was created to provide seed funding to catalyse novel, high-risk, high-reward translational research. Preliminary data is not required.
The budget of the Rapid Response: Canada 2019 program has been increased to a maximum of $300,000 over up to 18 months.
Expanding the type of complementary approaches eligible for funding to other lifestyle interventions including but not limited to: speech therapy, cognitive therapy, music therapy, social interaction, if these applications meet our other scope criteria and have specific supportive evidence/justification (from published literature or unpublished data) to warrant further investigation.
Encouraging applications that bring in other fields such as: AI, big data, machine learning, data science, and computer science.
Goal: To provide seed funding for novel, high-risk, high-reward, translational research that will accelerate the development of therapeutics for neurodegenerative diseases of aging.
Funding: A maximum of $300,000 over up to 18 months per project.
Applicant Eligibility: Eligible Principal Applicants must be working in Canada at least 30% of the time at or above the level of Postdoctoral researcher, and be affiliated with a Canada Revenue Agency-qualified donee institution located in Canada. Co-Applicants/Collaborators must be at the post-doctoral level or above and can be working outside Canada.
If the Principal Applicant is not appointed at the institution from which they are applying, they need to apply with a research supervisor (an “Administrative Supervisor”) who is at or above the level of Assistant Professor or equivalent, with an appointment at the institution from which they are applying.
Applicants may appear in any role on any number of projects.
Project Eligibility: Projects must meet two conditions to be eligible:
- Be translational research that helps accelerate the development of therapeutics for neurodegenerative diseases of aging
- Be the development of a therapeutic and/or tool, and/or select complementary approaches (Please refer to the AD/PD Program Details for more information)
*Preliminary data is not required for this program
Please refer to What We Fund for Institute definitions of neurodegenerative diseases of aging, translational research, therapeutic/tool, and complementary approaches.
The Rapid Response program will have multiple calls per year, alternating between two different disease groups (outlined below). Applicants should apply to the group best suited to their project.
Alzheimer’s & Related Diseases:
- Alzheimer's disease
- Frontotemporal dementia
- Mild cognitive impairment
- Vascular contributions to the above
- Prodromes to the above
The Institute welcomes additional inquiries about this program, including whether a potential idea is in scope. For questions related to the Alzheimer’s & Related Diseases program, please contact Rene Prashad.
There are two stages of the application process:
- Letter of Intent (LOI)
- Full Proposal
An application requires the submission of a Letter of Intent which will be reviewed by our scientific review committee. Applicants with high potential projects will then be invited to submit a Proposal. Instructions for submitting the Proposal will be sent to those invited.
Alzheimer’s & Related Diseases (AD, FTD, MCI, and vascular contributions and prodromes to the listed diseases)
|Alzheimer’s & Related Diseases:|
|Program opens:||Currently Open|
|LOI deadline:||April 1, 2019 at 2:00pm EDT|
|Proposal deadline:||July 30, 2019 at 2:00pm EDT|
|Anticipated award notification:||October 2019|
The Institute will hold a Program Information Webinar for each disease focus, to provide further details on the program and answer any questions. However, if you have questions specific to your project (e.g., project scope), we encourage you to contact us.
Alzheimer’s & Related Diseases: February 27, 2019 at 1:00pm EST
Register for this webinar here